NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/05/2024
Voltar para busca
Dado oficial do USPTO
OXYGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
04/05/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
40, 42
Data de depósito
15/01/2020
Data de registro
02/11/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/11/2021
Última transação
02/11/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
B-6041 Gosselies, BE
Examinador
BARAHONA, BYRON
Unidade examinadora
N90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
HENOGEN
N. P. (pessoa física)
Representantes
Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Supply in the nature of custom manufacture of production units for biological moleculesparticularly viral vectors and monoclonal antibodiesin the pharmaceutical and biopharmaceutical field; contract manufacturing for others of biological moleculesparticularly viral vectors and monoclonal antibodiesin the pharmaceutical and biopharmaceutical field; production in the nature of custom manufacture of biological moleculesparticularly viral vectors and monoclonal antibodiesin the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Classe 42
Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological moleculesparticularly viral vectors and monoclonal antibodiesin the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/04/2022
FIMP
FINAL DISPOSITION PROCESSED
21/04/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/02/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
02/11/2021
DOCK
ASSIGNED TO EXAMINER
23/08/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/08/2021
PUBO
PUBLISHED FOR OPPOSITION
17/08/2021
GPNX
NOTIFICATION PROCESSED BY IB
14/08/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/07/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
28/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/07/2021
ALIE
ASSIGNED TO LIE
09/07/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/05/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
10/05/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/04/2021
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/04/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/03/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
26/01/2021
GNSL
LETTER OF SUSPENSION E-MAILED
26/01/2021
CNSL
SUSPENSION LETTER WRITTEN
26/01/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
19/01/2021
EXPI
EX PARTE APPEAL-INSTITUTED
19/01/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
19/01/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
19/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
20/07/2020
GNFR
FINAL REFUSAL E-MAILED
20/07/2020
CNFR
FINAL REFUSAL WRITTEN
20/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/07/2020
RFNT
REFUSAL PROCESSED BY IB
15/05/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/04/2020
RFRR
REFUSAL PROCESSED BY MPU
28/04/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/04/2020
CNRT
NON-FINAL ACTION WRITTEN
10/04/2020
DOCK
ASSIGNED TO EXAMINER
01/04/2020
MAFR
APPLICATION FILING RECEIPT MAILED
17/03/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/03/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/03/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OXYGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.